Chest pain with spurious ST-segment elevation.

and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor— after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61: 873–880. 12. Kubitza D, Becka M, Roth A, Mueck W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757–2765. 13. Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, Lufft V, Wand DD, Philipp T, Bruck H. Effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol 2010;70:703–712. 14. Fox KAA, Piccini JP, Wojdyla D, Becker CR, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387–2394. First published on 28 August 2011. doi:10.1093/eurheartj/ ehr342. 15. Eikelboom J, Wallentin L, Connolly S, Ezekowitz M, Healey J, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener H, Franzosi M, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation 2011; 123:2363–2372.